Get the Stockscreener App
0.584
2.01%
-0.012
Pre-market:
.57
-0.014
-2.40%
VolitionRX Ltd stock is traded at $0.584, with a volume of 168.81K.
It is down -2.01% in the last 24 hours and down -13.17% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.596
Open:
$0.6
24h Volume:
168.81K
Relative Volume:
0.66
Market Cap:
$56.05M
Revenue:
$1.29M
Net Income/Loss:
$-29.87M
P/E Ratio:
-1.6222
EPS:
-0.36
Net Cash Flow:
$-14.70M
1W Performance:
-5.35%
1M Performance:
-13.17%
6M Performance:
-8.22%
1Y Performance:
-45.67%
1-Day Range:
$0.575
$0.60
1-Week Range:
$0.575
$0.625
52-Week Range:
$0.4301
$1.23
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.584 | 56.05M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
580.57 | 222.07B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
215.01 | 154.61B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.04 | 41.95B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
465.03 | 38.08B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
200.04 | 36.31B | 15.32B | 1.41B | 1.96B | 7.62 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRx reports expanded global reach in 2024 - Investing.com India
VolitionRx's Nu.Q® Vet Cancer Test Hits Major Milestone: 110,000+ Tests Sold Across 20 Countries - StockTitan
VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock By Investing.com - Investing.com Nigeria
Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Australia
Volitionrx director Innes buys $99,999 in common stock - Investing.com India
VolitionRx chief scientific officer Micallef acquires $24,999 in stock By Investing.com - Investing.com Australia
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock - Investing.com
SEC Form 424B5 filed by VolitionRX Limited - Quantisnow
Form 424B5 VOLITIONRX LTD - StreetInsider.com
VolitionRx announces pricing of up to $1.9M registered direct offering - MSN
VolitionRx announces $1.9 million stock sale By Investing.com - Investing.com Australia
VolitionRx Secures $1.9M Financing with Insider Backing, Includes Strategic Warrant Package - StockTitan
VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs. - Zacks Small Cap Research
VolitionRx: Big EU Trials On Deck - Investing.com
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Benchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX) - MarketBeat
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VolitionRx Limited (AMEX:VNRX) Q3 2024 Earnings Call Transcript - Insider Monkey
VolitionRX: Q3 Earnings Snapshot - New Haven Register
VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
VolitionRx Posts Strong Q3 Growth and Strategic Advances - TipRanks
Lagoda Investment Management's Strategic Acquisition in Volition - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in VolitionRX Ltd - GuruFocus.com
VolitionRX Ltd Reports Q3 Revenue of $475,000, Missing Estimates of $0.65 Million - GuruFocus.com
VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to L - GuruFocus.com
VolitionRx (VNRX) Sets Q3 2024 Earnings Call: Key Executives to Present Financial Results | VNRX Stock News - StockTitan
Volition Appoints Timothy I. Still as Chairman – Company Announcement - Financial Times
VolitionRx (NYSE:VNRX) Now Covered by StockNews.com - Defense World
Abionic’s test enters increasingly competitive sepsis fray - BioWorld Online
VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com - Defense World
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar - Quantisnow
VolitionRx adds Dr. Ethel Rubin to its board By Investing.com - Investing.com South Africa
VolitionRx adds Dr. Ethel Rubin to its board - Investing.com India
Volition Appoints Dr. Ethel Rubin as an Independent Director - Quantisnow
VolitionRx announces executive employment updates - Investing.com India
Agency News | ⚡Tamil Nadu’s Veterinary Varsity Directed by High Court To Consider Transgender Student’s Application - LatestLY
Madras HC directs TN veterinary varsity to not reject transgender's application over identity - Hindustan Times
Madras High Court Orders TN Veterinary University to Accept Transgender Candidate's Application - Law Trend
Don't reject transgender's application over identity HC tells TN veterinary varsity - The Week
Madras High Court Upholds Transgender Rights for Veterinary Course Admissions - Devdiscourse
Volato Facing Class-action WARN Act Lawsuit - Aviation International News
VolitionRx offers oncology assets for licensing - Investing.com India
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.26%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):